TRINITY BIOTECH PLC (TRIB) Form 6-K — Jun 18, 2026
Trinity Biotech reported first quarter 2026 revenue of $10.8 million, a 43% increase compared to $7.6 million in the prior year period, driven by strong growth in rapid HIV and hemoglobin product sales. The company also achieved a significant improvement in gross margin, which expanded to 35.4% from 25.2%, while the net loss narrowed to $4.4 million from $8.8 million. To support its 2026 revenue and profitability targets, the company announced it received purchase orders for over 2 million units of its TrinScreen HIV rapid test scheduled for fulfillment in the third quarter.
Key figures
- Revenue
- $10.8m
- Net Income
- -$4.4m
- Revenue Yoy
- 43%
- Gross margin
- 35.4%
- Gross profit
- $3.8m
- Adjusted ebitda
- -$1.1m
- Trinscreen orders
- 2 million units
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.